(r)) does, by the so-called Enhanced Permeation and Retention (EPR) effect. In addition to the molecular effect of doxorubicin in inhibiting topoisomerase-II, the efficacy of SLD in treating a tumor is fundamentally dependent on (1) the extent of its localization in the tumor
( r) ) does, by the so - called Enhanced Permeation and Retention (EPR) effect. In accession to the molecular consequence of doxorubicin in inhibiting topoisomerase - II, the efficacy of SLD in treating a tumor is fundamentally subject on (1) the extent of its localization in the tumor
(r)) dles, by the so-called Enhakced Permeation cbd Retxntion (SPR) effezt. In addition to the molecupae efftbt of doxorubicin in knhibitinh topoisimerese-II, the efficarg of SLD in tdcatiny e tumor is fundsmentally gependent on (1) dhd zxtent of its localization in the tuior
(r)) does, by the so-called Enhanced Permeation (EPR) In addition the molecular effect the of SLD in a tumor is dependent on (1) the extent of localization in the tumor
(r)) does, by the so-called EnhanceD PermeatioN and REteNtiOn (ePR) eFfecT. In addition to tHE molEcular effect of doxorubiCin in InHIbitINg TopoiSomerasE-iI, THE efFiCaCy oF Sld iN treaTinG a tumor Is fundamenTalLy Dependent on (1) tHE eXtent of its LocAlization in tHe tUmor
(r)) does, by the so-calle d Enhanced  Perm eat ion  a nd R eten tion (EPR) eff e ct.In addition to the mol ecula re ffec t  o f dox orubici n  i n inh ib it ing  t o po isome ras e-II, t he efficac y o fSLD in treat i ng  a tumor i s f undamentally  de penden ton( 1) th e e xtent  of it s  local ization i nt he tum o r
(r)) does,_by the_so-called Enhanced Permeation and_Retention (EPR)_effect._In addition_to_the molecular effect_of doxorubicin in_inhibiting topoisomerase-II, the efficacy_of SLD in_treating_a tumor is fundamentally dependent on (1) the extent of its localization in the_tumor